MaaT Pharma Announces Positive Safety Interim Analysis from DSMB for Phase 2b Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT

2 months ago 9
Read Entire Article
  1. Homepage
  2. Finance
  3. MaaT Pharma Announces Positive Safety Interim Analysis from DSMB for Phase 2b Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT

Related

XCF Global appoints board of directors following Nasdaq listing

XCF Global appoints board of directors following Nasdaq list...

3 minutes ago 0
Curaleaf Appoints CPG Leader Rahul Pinto as President, Bolsters Marketing Leadership Team

Curaleaf Appoints CPG Leader Rahul Pinto as President, Bolst...

3 minutes ago 0
NYSE-parent Intercontinental Exchange to dual list on NYSE Texas

NYSE-parent Intercontinental Exchange to dual list on NYSE T...

3 minutes ago 0

Trending

Popular

College football by the odds: Vegas picks and preview of Ohio State vs. Notre Dame

College football by the odds: Vegas picks and preview of Ohi...

4 months ago 270
Australian whose blood saved 2.4 million babies dies

Australian whose blood saved 2.4 million babies dies

3 months ago 152
What to do in Las Vegas this week: January 2-8

What to do in Las Vegas this week: January 2-8

5 months ago 148
TOUS les JOURS Opens in Henderson!

TOUS les JOURS Opens in Henderson!

4 months ago 116
Sole mates: Find the perfect shoes for your fitness journey

Sole mates: Find the perfect shoes for your fitness journey

4 months ago 112
English (US) English (US) ·
About Us · Contact Us · Terms & Conditions ·

© Sincity Press 2025. All rights are reserved